Skip to main content

Table 1 Reproductive performance of p53+/- females treated with cyclophosphamide (CP) and tested on day 16 of pregnancy.

From: Teratogen-induced alterations in microRNA-34, microRNA-125b and microRNA-155 expression: correlation with embryonic p53 genotype and limb phenotype

 

Groups of females

Indices

Control

CP (12.5 mg/kg)

CP (20 mg/kg)

CP (40 mg/kg)

Number of pregnant females

8

10

14

10

Implantation sites/litter

66/8.3

84/8.4

106/7.6

83/8.3

Percent of resorptions

(arcsine, mean ± SE)

6.1

(16.2 ± 3.4) a

4.8

(15.4 ± 2.5) a

13.2

(23.5 ± 3.6)a

26.5

(32.0 ± 2.0) b

Number of live fetuses

    

Total

62

80

92

61

p53+/+

18 (29%)

14 (17.5%)

16 (17.4%)

18 (29.5%)

p53+/-

27 (43.6%)

46 (57.5%)

48 (52.2%)

36 (59%)

p53-/-

17 (27.4%)

20 (25%)

28 (30.4%)

7 (11.5%)

  1. Superscripts denote results of statistical analysis of values within a row. Values not sharing common superscripts are significantly different (the GT-2 test, p < 0.05).